View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:
Presenter:
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Follow along with the slides at:
https://bit.ly/3hNfHII
Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen
Prof Gail Matthews, MD, PhD
Released: January 25, 2022
Slides from Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in experienced patients who are suppressed
John D. Baxter, MD
Released: January 24, 2022
Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging
Anonymous Patient
Released: January 11, 2022
Audio from Dr. Karen Ha and Clinical Care Options (CCO): Data suggest there is a role for PIs in current practice for rapid initiation and experienced patients
Karen Ha, MD
Released: January 6, 2022
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.